Beyond aspirin - Cancer prevention with statins, metformin and bisphosphonates

Nature Reviews Clinical Oncology

Volumn 10, Issue 11, 2013, Pages 625-642

  Gronich, Naomi ^a   Rennert, Gad ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENYLATE KINASE; ANASTROZOLE; ATORVASTATIN; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; CLODRONIC ACID; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVALONIC ACID; MEVINOLIN; PAMIDRONIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BONE METASTASIS; BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COLON CANCER; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; GENETIC RISK; HMGCR GENE; HUMAN; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LOW DRUG DOSE; LUNG ADENOMA; LUNG METASTASIS; LUNG TUMOR; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PHARMACOGENETICS; PRIORITY JOURNAL; RECTUM ADENOMA; REVIEW; RHABDOMYOLYSIS; SINGLE DRUG DOSE; SLC22A1 GENE; VDR GENE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84887410335     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.169     Document Type: Review

References (231)

1. Cuzick, J. et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol. 12, 496-503 (2011
2. Thun, M. J., Jacobs, E. J. & Patrono, C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9, 259-267 (2012
3. Cuzick, J. et al. Aspirin and non-steroidal anti inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol. 10, 501-507 (2009
4. Rennert, G., Rennert, H. S., Pinchev, M. & Gruber, S. B. A case-control study of levothyroxine and the risk of colorectal cancer. J. Natl Cancer Inst. 102, 568-572 (2010
5. Arrieta, O. et al. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer 107, 1852-1858 (2006
6. Yasuda, T. et al. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Res. 6, 1852-1860 (2008
7. Umar, A., Dunn, B. K. & Greenwald, P. Future directions in cancer prevention. Nat. Rev. Cancer 12, 835-848 (2012
8. Sperati, F. et al. Vitamin D supplementation and breast cancer prevention: A systematic review and meta-analysis of randomized clinical trials. PLoS ONE 8, e69269 (2013
9. Murphy, M. S. & O'Brien, T. in Pharmacology and Therapeutics: Principles to practice Ch. 23 (eds Waldman, S. A. & Terzic, A.) 303-320 (Elsevier, Amsterdam, 2009
10. Law, M. & Rudnicka, A. R. Statin safety: A systematic review. Am. J. Cardiol. 97, 52C-60C (2006
11. Gazzerro, P. et al. Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102-146 (2012
12. Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977-987 (2005
13. Kwak, B., Mulhaupt, F., Myit, S. & Mach, F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402 (2000
14. Goldstein, J
15. Clendening, J. W. et al. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl Acad. Sci. USA 107, 15051-15056 (2010
16. Inano, H., Suzuki, K., Onoda, M. & Wakabayashi, K. Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis 18, 1723-1727 (1997
17. Alonso, D. F. et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res. Treat. 50, 83-93 (1998
18. Campbell, M. J. et al. Breast cancer growth prevention by statins. Cancer Res. 66, 8707-8714 (2006
19. Kubatka, P. et al. Immunohistochemical and histomorphological analysis of rat mammary tumors after simvastatin treatment. Neoplasma 59, 516-523 (2012
20. Yu, X. et al. BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1 CDK4 p21WAF1/CIP1 pathway: Analyses using a breast cancer cell line and tumoral xenograft model. Int. J. Oncol. 33, 555-563 (2008
21. Hawk, M. A., Cesen, K. T., Siglin, J. C., Stoner, G. D. & Ruch, R. J. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett. 109, 217-222 (1996
22. Swamy, M. V. et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCM in mice. Cancer Res. 66, 7370-7377 (2006
23. Suh, N. et al. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats. Cancer Prev. Res. (Phila.) 4, 1895-1902 (2011
24. Cho, S. J. et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int. J. Cancer 123, 951-957 (2008
25. Kodach, L. L. et al. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133, 1272-1281 (2007
26. Mohammed, A. et al. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int. J. Cancer 131, 1951-1962 (2012
27. Sumi, S. et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103, 982-989 (1992
28. Gbelcová, H. et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int. J. Cancer 122, 1214-1221 (2008
29. Björkhem-Bergman, L., Acimovic, J., Torndal, U. B., Parini, P. & Eriksson, L. C. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res. 30, 1105-1112 (2010
30. Acimovic, J., Lövgren-Sandblom, A., Eriksson, L. C. & Björkhem-Bergman, L. The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone. Biochem. Biophys. Res. Commun. 425, 348-352 (2012
31. Taras, D. et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J. Hepatol. 46, 69-76 (2007
32. Cao, Z. et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 71, 2286-2297 (2011
33. Matsuura, M. et al. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol. Rep. 25, 41-47 (2011
34. Kochuparambil, S. T., Al-Husein, B., Goc, A., Soliman, S. & Somanath, P. R. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J. Pharmacol. Exp. Ther. 336, 496-505 (2011
35. Takwi, A. A. et al. A statin-regulated microRNA represses human c Myc expression and function. EMBO Mol. Med. 4, 896-909 (2012
36. Kidera, Y. et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled coil containing protein kinase pathway. J. Exp. Clin. Cancer Res. 29, 127 (2010
37. .[No authors listed] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349-1357 (1998
38. Shepherd, J. et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360, 1623-1630 (2002
39. Bjerre, L. M. & LeLorier, J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am. J. Med. 110, 716-723 (2001
40. Jacobs, E. J., Newton, C. C., Thun, M. J. & Gapstur, S. M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 71, 1763-1771 (2011
41. Friis, S. et al. Cancer risk among statin users: A population-based cohort study. Int. J. Cancer 114, 643-647 (2005
42. Farwell, W. R. et al. The association between statins and cancer incidence in a veterans population. J. Natl Cancer Inst. 100, 134-139 (2008
43. Haukka, J. et al. Incidence of cancer and statin usage-record linkage study. Int. J. Cancer 126, 279-284 (2010
44. Fröhlich, G. M. et al. Statins and the risk of cancer after heart transplantation. Circulation 126, 440-447 (2012
45. Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer related mortality. N. Engl. J. Med. 367, 1792-1802 (2012
46. Blais, L., Desgagné, A. & LeLorier, J. 3 Hydroxy 3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch. Intern. Med. 160, 2363-2368 (2000
47. Graaf, M. R., Beiderbeck, A. B., Egberts, A. C., Richel, D. J. & Guchelaar, H. J. The risk of cancer in users of statins. J. Clin. Oncol. 22, 2388-2394 (2004
48. Cauley, J. A. et al. Lipid-lowering drug use and breast cancer in older women: A prospective study. J. Womens Health (Larchmt) 12, 749-756 (2003
49. Cauley, J. A. et al. Statin use and breast cancer: Prospective results from the Women's Health Initiative. J. Natl Cancer Inst. 98, 700-707 (2006
50. Kwan, M. L., Habel, L. A., Flick, E. D., Quesenberry, C. P. & Caan, B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res. Treat. 109, 573-579 (2008
51. Ahern, T. P. et al. Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J. Natl Cancer Inst. 103, 1461-1468 (2011
52. Boudreau, D. M. et al. The association between 3 hydroxy 3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: A case-control study. Cancer 100, 2308-2316 (2004
53. Lee, J. E. et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev. Res. (Phila.) 4, 1808-1815 (2011
54. Simon, M. S. et al. Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann. Epidemiol. 22, 17-27 (2012
55. Poynter, J. N. et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352, 2184-2192 (2005
56. Samadder, N. J. et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117, 1640-1648 (2011
57. Vinogradova, Y., Hippisley-Cox, J., Coupland, C. & Logan, R. F. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase 2 inhibitors: Nested case-control study. Gastroenterology 133, 393-402 (2007
58. Hoffmeister, M., Chang-Claude, J. & Brenner, H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based case-control study. Int. J. Cancer 121, 1325-1330 (2007
59. Hachem, C., Morgan, R., Johnson, M., Kuebeler, M. & El-Serag, H. Statins and the risk of colorectal carcinoma: A nested case-control study in veterans with diabetes. Am. J. Gastroenterol. 104, 1241-1248 (2009
60. Robertson, D. J. et al. Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin. Gastroenterol. Hepatol. 8, 1056-1061 (2010
61. Broughton, T., Sington, J. & Beales, I. L. Statin use is associated with a reduced incidence of colorectal cancer: A colonoscopy-controlled case-control study. BMC Gastroenterol. 12, 36 (2012
62. Lakha, F. et al. Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage. BMC Cancer 12, 487 (2012
63. Broughton, T., Sington, J. & Beales, I. L. Statin use is associated with a reduced incidence of colorectal adenomatous polyps. Int. J. Colorectal Dis. 28, 469-476 (2013
64. Kawata, S. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84, 886-891 (2001
65. Kastelein, F. et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 141, 2000-2008 (2011
66. Kantor, E. D., Onstad, L., Blount, P. L., Reid, B. J. & Vaughan, T. L. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 21, 456-461 (2012
67. Liu, W., Choueiri, T. K. & Cho, E. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 118, 797-803 (2012
68. Tsan, Y. T., Lee, C. H., Wang, J. D. & Chen, P. C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol. 30, 623-630 (2012
69. Khurana, V., Bejjanki, H. R., Caldito, G. & Owens, M. W. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 131, 1282-1288 (2007
70. Nguyen, D. M., Richardson, P. & El-Serag, H. B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 138, 2260-2266 (2010
71. Beales, I. L., Vardi, I., Dearman, L. & Broughton, T. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: A case control study. Dis. Esophagus http://dx.doi.org/10.1111/j.1442- 2050201201412x.
72. Chiu, H. F., Ho, S. C., Chang, C. C., Wu, T. N. & Yang, C. Y. Statins are associated with a reduced risk of gastric cancer: A population-based case-control study. Am. J. Gastroenterol. 106, 2098-2103 (2011
73. Khurana, V., Sheth, A., Caldito, G. & Barkin, J. S. Statins reduce the risk of pancreatic cancer in humans: A case-control study of half a million veterans. Pancreas 34, 260-265 (2007
74. El-Serag, H. B., Johnson, M. L., Hachem, C. & Morgana, R. O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136, 1601-1608 (2009
75. Chiu, H. F., Ho, S. C., Chen, C. C. & Yang, C. Y. Statin use and the risk of liver cancer: A population-based case-control study. Am. J. Gastroenterol. 106, 894-898 (2011
76. Kaye, J. A. & Jick, H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer 90, 635-637 (2004
77. Setoguchi, S., Glynn, R. J., Avorn, J., Mogun, H. & Schneeweiss, S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115, 27-33 (2007
78. Smeeth, L., Douglas, I., Hall, A. J., Hubbard, R. & Evans, S. Effect of statins on a wide range of health outcomes: A cohort study validated by comparison with randomized trials. Br. J. Clin. Pharmacol. 67, 99-109 (2009
79. Friedman, G. D. et al. Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361, 859 recipients. Pharmacoepidemiol. Drug Saf. 17, 27-36 (2008
80. Marelli, C. et al. Statins and risk of cancer: A retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J. Am. Coll. Cardiol. 58, 530-537 (2011
81. Vinogradova, Y., Coupland, C. & Hippisley-Cox, J. Exposure to statins and risk of common cancers: A series of nested case-control studies. BMC Cancer 11, 409 (2011
82. Boudreau, D. M., Yu, O., Miglioretti, D. L., Buist, D. S., Heckbert, S. R. & Daling, J. R. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol. Biomarkers Prev. 16, 416-421 (2007
83. Kaye, J. A., Meier, C. R., Walker, A. M. & Jick, H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br. J. Cancer 86, 1436-1439 (2002
84. Woditschka, S., Habel, L. A., Udaltsova, N., Friedman, G. D. & Sieh, W. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol. Biomarkers Prev. 19, 2479-2487 (2010
85. Jacobs, E. J. et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J. Natl Cancer Inst. 98, 69-72 (2006
86. Ng, K. et al. Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803. J. Natl Cancer Inst. 103, 1540-1551 (2011
87. Bertagnolli, M. M. et al. Statin use and colorectal adenoma risk: Results from the adenoma prevention with celecoxib trial. Cancer Prev. Res. (Phila.) 3, 588-596 (2010
88. Coogan, P. F., Smith, J. & Rosenberg, L. Statin use and risk of colorectal cancer. J. Natl Cancer Inst. 99, 32-40 (2007
89. Yang, Y. X. et al. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 17, 869-876 (2008
90. Cheng, M. H. et al. Statin use and the risk of colorectal cancer: A population-based case-control study. World J. Gastroenterol. 17, 5197-5202 (2011
91. Bradley, M. C., Hughes, C. M., Cantwell, M. M. & Murray, L. J. Statins and pancreatic cancer risk: A nested case-control study. Cancer Causes Control 21, 2093-2100 (2010
92. Yu, O., Boudreau, D. M., Buist, D. S. & Miglioretti, D. L. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control 20, 609-616 (2009
93. Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996
94. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007 (2002
95. Pedersen, T. R. et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol. 86, 257-262 (2000
96. Strandberg, T. E. et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364, 771-777 (2004
97. Bulbulia, R. et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: A randomised controlled trial. Lancet 378, 2013-2020 (2011
98. Suissa, S., Dell'aniello, S., Vahey, S. & Renoux, C. Time-window bias in case-control studies: Statins and lung cancer. Epidemiology 22, 228-231 (2011
99. Notarnicola, M. et al. Up-regulation of 3 hydroxy 3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res. 24, 3837-3842 (2004
100. Sharad, S. et al. Prostate cancer gene expression signature of patients with high body mass index. Prostate Cancer Prostatic Dis. 14, 22-29 (2011
101. Higgins, M. J. et al. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res. Treat. 131, 915-924 (2012
102. Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J. & White, C. M. Statins and cancer risk: A meta-analysis. JAMA 295, 74-80 (2006
103. Kuoppala, J., Lamminpää, A. & Pukkala, E. Statins and cancer: A systematic review and meta-analysis. Eur. J. Cancer 44, 2122-2132 (2008
104. Taylor, M. L., Wells, B. J. & Smolak, M. J. Statins and cancer: A meta-analysis of case-control studies. Eur. J. Cancer Prev. 17, 259-268 (2008
105. Bonovas, S., Filioussi, K., Flordellis, C. S. & Sitaras, N. M. Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients. J. Clin. Oncol. 25, 3462-3468 (2007
106. Cui, X. et al. Statin use and risk of pancreatic cancer: A meta-analysis. Cancer Causes Control 23, 1099-1111 (2012
107. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology 144, 323-332 (2013
108. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT01011478 (2012
109. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT00816244 (2012
110. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/study/NCT00637481 (2013
111. Reiner, Z. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 10, 453-464 (2013
112. Lipkin, S. M. et al. Genetic variation in 3 hydroxy 3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev. Res. (Phila.) 3, 597-603 (2010
113. Bailey, K. M. et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: The GEOSTAT 1 Study. Circ. Cardiovasc. Genet. 3, 276-285 (2010
114. Brautbar, A. et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 219, 737-742 (2011
115. Peters, B. J. et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 11, 1065-1076 (2010
116. Chasman, D. I. et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 5, 257-264 (2012
117. Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258 (2012
118. Power, D. G., Gloglowski, E. & Lipkin, S. M. Clinical genetics of hereditary colorectal cancer. Hematol. Oncol. Clin. North Am. 24, 837-859 (2010
119. Rizza, R. A. & Vella, A. in Pharmacology and Therapeutics: Principles to practice Ch. 37 (eds Waldman, S. A. & Terzic, A.) 557-570 (Elsevier, Amsterdam, 2009
120. Xu, J. et al. Insulin enhances growth hormone induction of the MEK/ERK signaling pathway. J. Biol. Chem. 281, 982-992 (2006
121. Bennett, W. L., Keeton, A. B., Ji, S., Xu, J. & Messina, J. L. Insulin regulation of growth hormone receptor gene expression: Involvement of both the PI 3 kinase and MEK/ERK signaling pathways. Endocrine 32, 219-226 (2007
122. Melander, O. et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 308, 1469-1475 (2012
123. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001
124. Shaw, R. J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646 (2005
125. Hemminki, A. et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998
126. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. & Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273 (2006
127. Zakikhani, M., Dowling, R. J., Sonenberg, N. & Pollak, M. N. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res. (Phila.) 1, 369-375 (2008
128. Ben Sahra, I. et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372 (2011
129. Deng, X. S. et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11, 367-376 (2012
130. Oliveras-Ferraros, C., Vazquez-Martin, A. & Menendez, J. A. Genome-wide inhibitory impact of the AMPK activator metformin on[kinesins, tubulins, histones, auroras and polo-like kinases] M phase cell cycle genes in human breast cancer cells. Cell Cycle 8, 1633-1636 (2009
131. Cufí, S. et al. Metformin lowers the threshold for stress-induced senescence: A role for the microRNA 200 family and miR 205. Cell Cycle 11, 1235-1246 (2012
132. Zhuang, Y. & Miskimins, W. K. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol. Cancer Res. 9, 603-615 (2011
133. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507-7511 (2009
134. Oliveras-Ferraros, C. et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA 181a. Cell Cycle 10, 1144-1151 (2011
135. Buzzai, M. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752 (2007
136. Memmott, R. M. et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3, 1066-1076 (2010
137. Algire, C., Zakikhani, M., Blouin, M. J., Shuai, J. H. & Pollak, M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr. Relat. Cancer 15, 833-839 (2008
138. Schneider, M. B. et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-1270 (2001
139. Blandino, G. et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c MYC. Nat. Commun. 3, 865 (2012
140. Rattan, R., Graham, R. P., Maguire, J. L., Giri, S. & Shridhar, V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13, 483-491 (2011
141. Shank, J. J. et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol. 127, 390-397 (2012
142. Phoenix, K. N., Vumbaca, F. & Claffey, K. P. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA MB 435 breast cancer model. Breast Cancer Res. Treat. 113, 101-111 (2009
143. Martin, M. J., Hayward, R., Viros, A. & Marais, R. Metformin accelerates the growth of BRAFV600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2, 344-355 (2012
144. Larsson, S. C., Orsini, N. & Wolk, A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J. Natl Cancer Inst. 97, 1679-1687 (2005
145. Michels, K. B. et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26, 1752-1758 (2003
146. Redaniel, M. T., Jeffreys, M., May, M. T., Ben Shlomo, Y. & Martin, R. M. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: A population-based cohort study among British women. Cancer Causes Control 23, 1785-1795 (2012
147. Boyle, P. et al. Diabetes and breast cancer risk: A meta-analysis. Br. J. Cancer 107, 1608-1617 (2012
148. Luo, J. et al. Diabetes and lung cancer among postmenopausal women. Diabetes Care 35, 1485-1491 (2012
149. Newton, C. C., Gapstur, S. M., Campbell, P. T. & Jacobs, E. J. Type 2 diabetes mellitus, insulin use, and risk of bladder cancer in a large cohort study. Int. J. Cancer 132, 2186-2191 (2013
150. Kasper, J. S. & Giovannucci, E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 2056-2062 (2006
151. Johnson, J. A. et al. Diabetes and cancer (1): Evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55, 1607-1618 (2012
152. Decensi, A. et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev. Res. (Phila.) 3, 1451-1461 (2010
153. Noto, H., Goto, A., Tsujimoto, T. & Noda, M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS ONE 7, e33411 (2012
154. Zhang, Z. J. et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care 34, 2323-2328 (2011
155. Col, N. F., Ochs, L., Springmann, V., Aragaki, A. K. & Chlebowski, R. T. Metformin and breast cancer risk: A meta-analysis and critical literature review. Breast Cancer Res. Treat. 135, 639-646 (2012
156. Suissa, S. & Azoulay, L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 35, 2665-2673 (2012
157. Home, P. D. et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53, 1838-1845 (2010
158. Bonanni, B. et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J. Clin. Oncol. 30, 2593-2600 (2012
159. Niraula, S. et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res. Treat. 135, 821-830 (2012
160. Hadad, S. et al. Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window of opportunity, randomized trial. Breast Cancer Res. Treat. 128, 783-794 (2011
161. Hosono, K. et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila.) 3, 1077-1083 (2010
162. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT01312467 (2013
163. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT01793948 (2013
164. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT01447927 (2013
165. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT01905046 (2013
166. Higurashi, T. et al. Metformin efficacy and safety for colorectal polyps: A double-blind randomized controlled trial. BMC Cancer 12, 118 (2012
167. Wang, D. S. et al. Involvement of organic cation transporter 1 in the hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302, 510-515 (2002
168. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007
169. Zhou, K. et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117-120 (2011
170. Clarke, L. C. & Khosla, S. in Pharmacology and Therapeutics: Principles to practice Ch. 39 (eds Waldman, S. A. & Terzic, A.) 587-610 (Elsevier, Amsterdam, 2009
171. Russell, R. G. Bisphosphonates: From bench to bedside. Ann. N. Y. Acad. Sci. 1068, 367-401 (2006
172. Tang, X. et al. Bisphosphonates suppress insulin-like growth factor 1 induced angiogenesis via the HIF-1α/VEGF signaling pathways in human breast cancer cells. Int. J. Cancer 126, 90-103 (2010
173. Senaratne, S. G., Mansi, J. L. & Colston, K. W. The bisphosphonate zoledronic acid impairs Ras membrane[correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer 86, 1479-1486 (2002
174. Hiraga, T., Williams, P. J., Ueda, A., Tamura, D. & Yoneda, T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 10, 4559-4567 (2004
175. Senaratne, S. G., Pirianov, G., Mansi, J. L., Arnett, T. R. & Colston, K. W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82, 1459-1468 (2000
176. Li, Y. Y. et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non small cell lung cancers. Lung Cancer 59, 180-191 (2008
177. Brown, H. K., Ottewell, P. D., Coleman, R. E. & Holen, I. The kinetochore protein Cenp F is a potential novel target for zoledronic acid in breast cancer cells. J. Cell. Mol. Med. 15, 501-513 (2011
178. Coscia, M. et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell. Mol. Med. 14, 2803-2815 (2010
179. Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z. & Colombo, M. P. Amino biphosphonate mediated MMP 9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438-11446 (2007
180. Daubiné, F., Le Gall, C., Gasser, J., Green, J. & Clézardin, P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst. 99, 322-330 (2007
181. Hashimoto, K. et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun. 354, 478-484 (2007
182. Santini, D. et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13 (15 Pt 1), 4482-4486 (2007
183. Santini, D. et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol. Immunother. 58, 31-38 (2009
184. Diel, I. J. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339, 357-363 (1998
185. Powles, T. et al. Randomized, placebo-controlled trial of clodronate in
186. Saarto, T., Vehmanen, L., Virkkunen, P. & Blomqvist, C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43, 650-656 (2004
187. Kristensen, B. et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 47, 740-746 (2008
188. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009
189. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG 12 randomised trial. Lancet Oncol. 12, 631-641 (2011
190. Aft, R. et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol. 11, 421-428 (2010
191. Coleman, R. E. et al. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365, 1396-1405 (2011
192. Coleman, R. E. et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 102, 1099-1105 (2010
193. Aft, R. L., Naughton, M., Trinkaus, K. & Weilbaecher, K. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br. J. Cancer 107, 7-11 (2012
194. Coleman, R. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann. Oncol. 24, 398-405 (2013
195. Paterson, A. H. et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B 34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13, 734-742 (2012
196. Newcomb, P. A., Trentham-Dietz, A. & Hampton, J. M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer 102, 799-802 (2010
197. Chlebowski, R. T. et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J. Clin. Oncol. 28, 3582-3590 (2010
198. Rennert, G., Pinchev, M. & Rennert, H. S. Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol. 28, 3577-3581 (2010
199. Monsees, G. M., Malone, K. E., Tang, M. T., Newcomb, P. A. & Li, C. I. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J. Natl Cancer Inst. 103, 1752-1760 (2011
200. Rennert, G., Pinchev, M., Rennert, H. S. & Gruber, S. B. Use of bisphosphonates and reduced risk of colorectal cancer. J. Clin. Oncol. 29, 1146-1150 (2011
201. Pazianas, M., Abrahamsen, B., Eiken, P. A., Eastell, R. & Russell, R. G. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study. Osteoporos. Int. 23, 2693-2701 (2012
202. Singh, H., Nugent, Z., Demers, A., Mahmud, S. & Bernstein, C. Exposure to bisphosphonates and risk of colorectal cancer: A population-based nested case-control study. Cancer 118, 1236-1243 (2012
203. Khalili, H., Huang, E. S., Ogino, S., Fuchs, C. S. & Chan, A. T. A prospective study of bisphosphonate use and risk of colorectal cancer. J. Clin. Oncol. 30, 3229-3233 (2012
204. Passarelli, M. N. et al. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.1930
205. Mason, M. D. et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J. Natl Cancer Inst. 99, 765-776 (2007
206. Green, J. et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ 341, c4444 (2010
207. Cardwell, C. R., Abnet, C. C., Cantwell, M. M. & Murray, L. J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304, 657-663 (2010
208. Chiang, C. H. et al. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study. J. Bone Miner. Res. 27, 1951-1958 (2012
209. Cardwell, C. R. et al. Exposure to oral bisphosphonates and risk of cancer. Int. J. Cancer 131, E717-E725 (2012
210. Liu, Y. et al. Bisphosphonate use and the risk of breast cancer: A meta-analysis of published literature. Clin. Breast Cancer 12, 276-281 (2012
211. Thosani, N. et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: A systematic review and meta-analysis. J. Clin. Oncol. 31, 623-630 (2013
212. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT00127205 (2013
213. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT00295646 (2013
214. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/record/NCT00295867 (2012
215. US National Library of Medicine. ClinicalTrials.gov[online], http://clinicaltrials.gov/ct2/show/NCT00892242 (2013
216. Marini, F. & Brandi, M. L. Pharmacogenetics of osteoporosis. F1000 Biol. Rep. 2, 63 (2010
217. Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491-501 (2012
218. Libby, G. et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32, 1620-1625 (2009
219. Currie, C. J., Poole, C. D. & Gale, E. A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777 (2009
220. Chlebowski, R. T. et al. Diabetes, metformin, and breast cancer in postmenopausal women. J. Clin. Oncol. 30, 2844-2852 (2012
221. Jiralerspong, S. et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27, 3297-3302 (2009
222. Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S. & Meier, C. R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33, 1304-1308 (2010
223. Bosco, J. L., Antonsen, S., Sørensen, H. T., Pedersen, L. & Lash, T. L. Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer Epidemiol. Biomarkers Prev. 20, 101-111 (2011
224. Bodmer, M., Becker, C., Meier, C., Jick, S. S. & Meier, C. R. Use of metformin is not associated with a decreased risk of colorectal cancer: A case-control analysis. Cancer Epidemiol. Biomarkers Prev. 21, 280-286 (2012
225. Bodmer, M., Becker, C., Jick, S. S. & Meier, C. R. Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer 78, 133-137 (2012
226. Smiechowski, B. B., Azoulay, L., Yin, H., Pollak, M. N. & Suissa, S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36, 124-129 (2013
227. Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M. & Abbruzzese, J. L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137, 482-488 (2009
228. Bodmer, M., Becker, C., Meier, C., Jick, S. S. & Meier, C. R. Use of antidiabetic agents and the risk of pancreatic cancer: A case-control analysis. Am. J. Gastroenterol. 107, 620-626 (2012
229. Hassan, M. M. et al. Association of diabetes duration and diabetes treatment with the risk of epatocellular carcinoma. Cancer 116, 1938-1946 (2010
230. Diel, I. J. et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up. Ann. Oncol. 19, 2007-2011 (2008
231. Newcomb, P. A., Trentham-Dietz, A. & Hampton, J. M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer 102, 799-802 (2010